Goldman Sachs Group, Inc. (The) reaffirmed their buy rating on shares of Eli Lilly and Company (NYSE:LLY) in a research report released on Thursday, October 5th. Goldman Sachs Group, Inc. (The) currently has a $95.00 target price on the stock, up from their prior target price of $92.00.
LLY has been the subject of a number of other reports. BidaskClub raised Eli Lilly and from a sell rating to a hold rating in a research note on Wednesday, June 14th. Barclays PLC raised their price objective on Eli Lilly and from $85.00 to $90.00 and gave the company an overweight rating in a research note on Tuesday, July 4th. BMO Capital Markets reissued a sell rating and set a $73.00 price objective on shares of Eli Lilly and in a report on Friday, August 4th. Berenberg Bank reissued a buy rating and set a $100.00 price objective on shares of Eli Lilly and in a report on Thursday, July 27th. Finally, Jefferies Group LLC reaffirmed a buy rating and issued a $96.00 price target (up previously from $93.00) on shares of Eli Lilly and in a research note on Thursday, July 13th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of Hold and a consensus price target of $88.97.
Shares of Eli Lilly and (NYSE LLY) opened at 86.06 on Thursday. The firm has a market capitalization of $90.79 billion, a PE ratio of 37.24 and a beta of 0.34. Eli Lilly and has a 52-week low of $64.18 and a 52-week high of $89.09. The company’s 50-day moving average is $83.56 and its 200 day moving average is $82.19.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same period last year, the company posted $0.86 EPS. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. Equities analysts expect that Eli Lilly and will post $4.16 earnings per share for the current fiscal year.
WARNING: “Goldman Sachs Group, Inc. (The) Reiterates Buy Rating for Eli Lilly and Company (NYSE:LLY)” was reported by BBNS and is the property of of BBNS. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/goldman-sachs-group-inc-the-reiterates-buy-rating-for-eli-lilly-and-company-lly/1701279.html.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. The ex-dividend date is Tuesday, November 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.42%. Eli Lilly and’s dividend payout ratio (DPR) is currently 90.04%.
In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the sale, the insider now owns 123,865,804 shares of the company’s stock, valued at $10,040,562,072.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 990,000 shares of company stock worth $82,949,650 in the last three months. 0.20% of the stock is currently owned by company insiders.
Several hedge funds have recently modified their holdings of LLY. BlackRock Inc. boosted its holdings in shares of Eli Lilly and by 2,628.5% in the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after purchasing an additional 59,978,664 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Eli Lilly and by 7,093.5% in the 2nd quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock valued at $769,774,000 after purchasing an additional 9,223,251 shares in the last quarter. Dodge & Cox boosted its holdings in shares of Eli Lilly and by 22,094.9% in the 2nd quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock valued at $493,138,000 after purchasing an additional 5,964,955 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Eli Lilly and by 91.1% in the 2nd quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock valued at $468,691,000 after purchasing an additional 2,714,505 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Eli Lilly and by 3.3% in the 1st quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after purchasing an additional 2,181,701 shares in the last quarter. 75.53% of the stock is currently owned by hedge funds and other institutional investors.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with our FREE daily email newsletter.